Bright Minds Biosciences

DRUG

The current Bright Minds Biosciences (DRUG) market capitalization is approximately CA$859.94M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Bright Minds Biosciences's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:41 PM Eastern Time

In the most recently reported quarter, Bright Minds Biosciences (DRUG) generated CA$0.00 in revenue, representing a +0.00% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately CA$0.00, implying an expected +0.00% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 2:22 AM Eastern Time

In the most recently reported fiscal year, Bright Minds Biosciences (DRUG) generated net income of CA$-12.23M, compared with CA$-2.80M in the prior fiscal year, representing a -336.46% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of CA$-89.44M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 2:22 AM Eastern Time

According to its latest quarterly filing, Bright Minds Biosciences (DRUG) reported EBITDA of CA$-4.34M. For the upcoming quarter, analyst consensus currently expects EBITDA of CA$-14.90M, reflecting assumptions around revenue trends, operating costs, scale efficiencies, and margin dynamics. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 2:22 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.00x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 2:22 AM Eastern Time

Based on the latest available data, Bright Minds Biosciences (DRUG) is currently trading at a last twelve months (LTM) P/E ratio of -63.83x. Looking forward, the stock trades at a next twelve months (NTM) P/E ratio of -11.65x, based on consensus earnings estimates. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 2:22 AM Eastern Time

In the most recently reported quarter, Bright Minds Biosciences (DRUG) revenue was CA$0.00, compared with analyst consensus expectations of CA$0.00, representing a +0.00% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were CA$-0.58, compared with consensus estimates of CA$-1.00, resulting in an +42.00% EPS surprise. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 2:22 AM Eastern Time

Bright Minds Biosciences (DRUG) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CA$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 2:22 AM Eastern Time

Analyst assessments of whether Bright Minds Biosciences (DRUG) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: CA$110.43Consensus price target: CA$77.00Implied return: -30.27% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 2:22 AM Eastern Time

Based on the latest available analyst coverage, Bright Minds Biosciences (DRUG) currently carries a Buy consensus rating. Analysts' average DRUG price target is CA$77.00. Relative to the current share price of CA$110.43, this suggests a potential price change of approximately -30.27%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 2:22 AM Eastern Time

Like other publicly traded stocks, Bright Minds Biosciences (DRUG) shares are bought and sold on stock exchanges such as CNSX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Bright Minds Biosciences (DRUG) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add DRUG to your watchlist.

Bright Minds Biosciences trades under the ticker symbol DRUG on the CNSX stock exchange. The ticker DRUG is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Bright Minds Biosciences (DRUG) employs approximately 26 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:41 PM Eastern Time

Bright Minds Biosciences (DRUG) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Bright Minds Biosciences (DRUG) stock peers based on overlapping products, services, and competitive dynamics:Denali Therapeutics (DNLI)Alto Neuroscience (ANRO)Mind Medicine (MindMed) (MNMD)Arcturus Therapeutics Holdings (ARCT)Stoke Therapeutics (STOK)Voyager Therapeutics (VYGR)Alector (ALEC)Praxis Precision Medicines (PRAX)Arrowhead Pharmaceuticals (ARWR)NRx Pharmaceuticals (NRXP) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Bright Minds Biosciences.